Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 05 Aug 2023
Iveric Bio receives US FDA approval for Izervay (avacincaptad pegol intravitreal solution), a new treatment for geographic atrophy
5 August 2023 - Izervay is the only approved GA treatment with a statistically significant reduction in the rate of geographic ...
Posted by Michael Wonder on 05 Aug 2023
Drug makers brace for list of first 10 drugs for US price negotiations
2 August 2023 - Drug makers are bracing for the US Government's announcement of the 10 prescription medicines that will ...
Posted by Michael Wonder on 05 Aug 2023
Alarmed by popularity of Ozempic and Wegovy, insurers wage multi-front battle
3 August 2023 - Patients are bracing for “D-Day,” the date their insurance companies will stop covering the drugs. Doctors ...
Posted by Michael Wonder on 05 Aug 2023
FDA approves first oral treatment for post-partum depression
4 August 2023 - Today, the US FDA approved Zurzuvae (zuranolone), the first oral medication indicated to treat post-partum depression in ...
Posted by Michael Wonder on 04 Aug 2023
Setmelanotide acetate for the treatment of people with obesity and hyperphagia associated with Bardet-Biedl syndrome
3 August 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 04 Aug 2023
Orchard Therapeutics completes submission of biologics license application for OTL-200 in MLD to US FDA
3 August 2023 - Four MLD patients identified from ~150,000 newborns screened in prospective studies suggests significantly higher incidence than previously ...
Posted by Michael Wonder on 04 Aug 2023
Mesoblast receives complete response from US FDA for biologics license application for steroid-refractory acute graft versus host disease in children
4 August 2023 - Mesoblast Limited today announced that the US FDA has provided a complete response to its biologics license ...
Posted by Michael Wonder on 03 Aug 2023
Aardvark Therapeutics announces receipt of FDA rare paediatric disease designation for Prader-Willi syndrome
3 August 2023 - Aardvark's Phase 2 trial of oral ARD-101 in young adults with Prader-Willi syndrome is now open ...
Posted by Michael Wonder on 03 Aug 2023
US FDA approves Merck’s Ervebo (Ebola Zaire vaccine, live) for use in children 12 months of age and older
3 August 2023 - Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease. ...
Posted by Michael Wonder on 03 Aug 2023
China’s NMPA accepts and grants priority review designation to the new drug application for Luye Pharma’s rotigotine extended release microspheres
1 August 2023 - The drug is the world’s first innovative microsphere formulation for treating Parkinson’s disease. ...
Posted by Michael Wonder on 03 Aug 2023
Jazz Pharmaceuticals enters into letter of intent with the pan-Canadian Pharmaceutical Alliance for Rylaze, helping address the unmet need of acute lymphoblastic leukaemia and lymphoblastic lymphoma patients across Canada
2 August 2023 - Jazz Pharmaceuticals today announced that the Company has entered into a letter of intent with the pan-Canadian ...
Posted by Michael Wonder on 03 Aug 2023
Health Canada authorises Tecvayli (teclistamab injection), a first in class bispecific antibody for the treatment of patients with relapsed or refractory multiple myeloma
2 August 2023 - Approval for Tecvayli, a subcutaneously administered therapy, is based on results from the Phase 1/2 MajesTEC-1 ...
Posted by Michael Wonder on 03 Aug 2023
PHARMAC secures supply of vaccines for New Zealanders
3 August 2023 - PHARMAC has confirmed supply agreements for a range of funded vaccines including those that protect against ...
Posted by Michael Wonder on 02 Aug 2023
FDA approves trifluridine and tipiracil with bevacizumab for previously treated metastatic colorectal cancer
2 August 2023 - Today, the FDA approved trifluridine and tipiracil (Lonsurf, Taiho Oncology) with bevacizumab, for metastatic colorectal cancer ...
Posted by Michael Wonder on 02 Aug 2023
Etranacogene dezaparvovec for the treatment of patients with moderately severe or severe haemophilia B
2 August 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...